(Q38060572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

review article

1 reference

title

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

1 reference

attention deficit hyperactivity disorder

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Carlos Knecht

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Nestor Szerman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

María I Martinez

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

1 reference

1 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

15-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40263-012-0019-9

18 February 2020

exact match

0 references

cites work

Attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Electrophysiological changes of cardiac function during antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Drug-induced prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Sudden death and use of stimulant medications in youths.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Involvement of amphetamines in sudden and unexpected death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Early repolarization in young children with attention-deficit/hyperactivity disorder versus normal controls: a retrospective preliminary chart review study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Electrocardiographic effects of methylphenidate overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Case report: intoxication with high dose of long-acting methylphenidate (Concerta(®)) in a suicidal 14-year-old girl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A case of suicide attempt with long-acting methylphenidate (Concerta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Amphetamine derivative related deaths.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A Review of the Cardiovascular Effects and Toxicity of Tricyclic Antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiovascular effects of atomoxetine in children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Isolated atomoxetine (Strattera) ingestions commonly result in toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Atomoxetine ingestions in children: a report from poison centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Seizures and prolonged QTc with atomoxetine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Isolated atomoxetine overdose resulting in seizure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Genetics, molecular mechanisms and management of long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Clonidine in Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Alpha2-adrenergic agonists in opioid withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Clonidine and guanfacine in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Case study: adverse response to clonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

QT interval increased after single dose of lofexidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Severe developmental disorders and bilingualism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Protective effects of centrally acting sympathomodulatory drugs on myocardial ischemia induced by sympathetic overactivity in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

ADHD drugs and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

ADHD drugs and serious cardiovascular events in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiovascular events and death in children exposed and unexposed to ADHD agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Methylphenidate and risk of serious cardiovascular events in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Stimulant use linked to sudden death in children without heart problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

The case-control study. A practical review for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Electrocardiographic screening in children with attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

European guidelines on managing adverse effects of medication for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Baseline values from the electrocardiograms of children and adolescents with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0019-9

Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.

21 January 2018

1 reference

12 December 2020

Childhood hyperactivity as a predictor of carotid artery intima media thickness over a period of 21 years: the cardiovascular risk in young Finns study

1 reference

12 December 2020

Effect of clonidine on heart rate variability in congestive heart failure

1 reference

12 December 2020

Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.

1 reference

12 December 2020

Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.

1 reference

12 December 2020

Acute oxcarbazepine and atomoxetine overdose with quetiapine

1 reference

12 December 2020

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry

1 reference

12 December 2020

Ventricular tachycardia associated with the administration of methylphenidate during guanethidine therapy

1 reference

12 December 2020

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults

1 reference

12 December 2020

Impairment associated with adult ADHD.

1 reference

12 December 2020

Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma

1 reference

12 December 2020

Cardiac risk assessment before the use of stimulant medications in children and youth

1 reference

12 December 2020

Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death

1 reference

12 December 2020

Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Clinical pharmacology of tomoxetine, a potential antidepressant.

1 reference

12 December 2020

Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder

1 reference

12 December 2020

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

1 reference

12 December 2020

Stimulant treatment of ADHD and risk of sudden death in children

1 reference

12 December 2020

Clonidine and sudden death

1 reference

12 December 2020

A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

The need for speed: an update on methamphetamine addiction

1 reference

12 December 2020

Case series: clonidine has no systematic effects on PR or QTc intervals in children

1 reference

12 December 2020

Acute myocardial infarction in a teenager due to Adderall XR

1 reference

12 December 2020

Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hy

1 reference

12 December 2020

Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Cardiovascular responses of hyperactive children to methylphenidate

1 reference

12 December 2020

Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center

1 reference

12 December 2020

Cardiovascular Safety of Stimulant Medications for Pediatric Attention-Deficit Hyperactivity Disorder

1 reference

12 December 2020

A Placebo-controlled study of three clonidine doses for smoking cessation

1 reference

12 December 2020

A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Cardiovascular side effects secondary to treatment with methylphenidate

1 reference

12 December 2020

Novel treatments for attention-deficit/hyperactivity disorder in children.

1 reference

12 December 2020

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.

1 reference

12 December 2020

How to predict the impact of methylphenidate on cardiovascular risk in children with attention deficit disorder: methylphenidate improves autonomic dysfunction in children with ADHD.

1 reference

12 December 2020

Methylphenidate-induced cardiac arrhythmias

1 reference

12 December 2020

Death in amphetamine users: causes and rates

1 reference

12 December 2020

Sudden death in children and adolescents

1 reference

12 December 2020

[Methylphenidate induced ST elevation acute myocardial infarction]

1 reference

12 December 2020

10.1007/S40263-012-0019-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23160939%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference